Genetic polymorphisms in the cytochrome P450 system and efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting

British Journal of Anaesthesia

Volumn 101, Issue 4, 2008, Pages 441-445

  Nielsen, M ^a   Olsen, N V ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CYTOCHROME P450; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; INHALATION ANESTHETIC AGENT; ISOFLURANE; ONDANSETRON; OPIATE; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ANESTHESIA COMPLICATION; CHEMOTHERAPY INDUCED EMESIS; DRUG EFFICACY; EDITORIAL; GENERAL ANESTHESIA; GENETIC POLYMORPHISM; HUMAN; POSTOPERATIVE COMPLICATION; POSTOPERATIVE NAUSEA; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PAIN; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; REGIONAL ANESTHESIA; RISK FACTOR; SOLITARY TRACT NUCLEUS; TREATMENT OUTCOME;

ANTIEMETICS; CYTOCHROME P-450 CYP2D6; HUMANS; POLYMORPHISM, GENETIC; POSTOPERATIVE NAUSEA AND VOMITING; SEROTONIN ANTAGONISTS; TREATMENT OUTCOME;

EID: 51849107008     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aen246     Document Type: Editorial

References (27)

1. Apfel CC, Läärä E, Koivuranta M, et al. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology 1999; 91: 693-700
2. Gan TJ. Risk factors for postoperative nausea and vomiting. Anesth Analg 2006; 102: 1884-98
3. Macario A, Weinger M, Carney S, et al. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg 1999; 89: 652-8
4. Gan TJ. Mechanisms underlying postoperative nausea and vomiting and neurotransmitter receptor antagonist-based pharmacotherapy. CNS Drugs 2007; 21: 813-33
5. 3 receptor antagonists for postoperative nausea and vomiting. CNS Drugs 2005; 19: 225-38
6. Ho KY, Gan TJ. Pharmacology, pharmacogenetics, and clinical efficacy of 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Curr Opin Anaesthesiol 2006; 19: 606-11
7. Blower PR. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications. Cancer J 2002; 8: 405-14
8. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 2004; 369: 23-37
9. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci 1999; 20: 342-9
10. Janicki PK. Cytochrome P450 2D6 metabolism and 5-hydroxytryptamine type 3 receptor antagonists for postoperative nausea and vomiting. Med Sci Monit 2005; 11: RA322-28
11. McElroy S, Sachse C, Brockmöller J, et al. CYP2D6 genotyping as an alternative to phenotyping for determination of metabolic status in a clinical trial setting. AAPS Pharmsci 2000; 2: E33
12. Institute of Environmental Medicine (Karolinska Institute). CYP2D6 allele nomenclature. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. Available from http://www.cypalleles.ki.se/cyp2d6.htm (accessed November 2007)
13. Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications. Oncologist 2006; 11: 126-35
14. Løvlie R, Daly AK, Matre GE, et al. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? Pharmacogenetics 2001; 11: 45-55
15. Gaedigk A, Bhatana A, Ndjountché L, et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans. Pharmacogenomics J 2005; 5: 173-82
16. Candiotti KA, Birnbach DJ, Lubarsky DA, et al. The impact of pharmacogenomics on postoperative nausea and vomiting. Anesthesiology 2005; 102: 543-9
17. Janicki PK, Schuler HG, Jarzembowski TM, et al. Prevention of postoperative nausea and vomiting with granisetron and dolasetron in relation to CYP2D6 genotype. Anesth Analg 2006; 102: 1127-33
18. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 2002; 20: 2805-11
19. Aklillu E, Persson I, Bertilsson L, et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 1996; 278: 441-6
20. Bathum L, Johansson I, Ingelman-Sundberg M, et al. Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 1998; 8: 119-23
21. London SJ, Daly AK, Leathart JB, et al. Genetic polymorphism of CYP2D6 and lung cancer risk in African-Americans and Caucasians in Los Angeles County. Carcinogenesis 1997; 18: 1203-14
22. Bozina N, Granic P, Lalic Z, et al. Genetic polymorphisms of cytochrome P450: CYP2C9, and CYP2D6 in Croatian population. Croat Med J 2003; 44: 425-8
23. Niewinski P, Orzechowska-Juzwenko K, Hurkacz M, et al. CYP2D6 extensive, intermediate, and poor phenotypes and genotypes in a Polish population. Eur J Clin Pharmacol 2002; 58: 533-5
24. Abraham BK, Adithan C, Shashindran CH, et al. Genetic polymorphism of CYP2D6 in a Keralite (South India) population. Br J Clin Pharmacol 2000; 49: 285-6
25. McLellan RA, Oscarson M, Seidegård J, et al. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetics 1997; 7: 187-91
26. López M, Guerrero J, Jung-Cook H, et al. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population. Eur J Clin Pharmacol 2005; 61: 749-54
27. Isaza CA, Henao J, Lopez AM, et al. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population. Methods Find Exp Clin Pharmacol 2000; 22: 695-705